Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
UMC Utrecht |
---|---|
Information provided by: | UMC Utrecht |
ClinicalTrials.gov Identifier: | NCT00189085 |
In the present study we investigate the effects of the cholesterol absorption inhibitor ezetimibe on posprandial lipemia and postprandial endothelial function in patients with the metabolic syndrome. The lipid-lowering effect of high-dose statin monotherapy on fasting lipids is equal to the combination therapy of low-dose statin and ezetimibe.
Condition | Intervention | Phase |
---|---|---|
Metabolic Syndrome |
Drug: simvastatin and ezetimibe |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment, Efficacy Study |
Official Title: | The Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Dysfunction in Patients With the Metabolic Syndrome. |
Estimated Enrollment: | 20 |
Study Start Date: | December 2004 |
Estimated Study Completion Date: | July 2005 |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Diagnosis of the metabolic syndrome according to ATP III criteria(4), including 3 or more of the following metabolic abnormalities:
Exclusion Criteria:
Study ID Numbers: | EZET |
Study First Received: | September 12, 2005 |
Last Updated: | September 15, 2005 |
ClinicalTrials.gov Identifier: | NCT00189085 |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Metabolic syndrome |
Metabolic Diseases Hyperlipidemias Simvastatin Ezetimibe |
Metabolic disorder Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Pathologic Processes Disease Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Syndrome Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |